These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35653782)

  • 21. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
    Johnson BA
    Biochem Pharmacol; 2008 Jan; 75(1):34-56. PubMed ID: 17880925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticonvulsants for alcohol dependence.
    Pani PP; Trogu E; Pacini M; Maremmani I
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD008544. PubMed ID: 24523233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider?
    Kelty E; Terplan M; Greenland M; Preen D
    Drugs; 2021 May; 81(7):739-748. PubMed ID: 33830479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls.
    Fairbanks J; Umbreit A; Kolla BP; Karpyak VM; Schneekloth TD; Loukianova LL; Sinha S
    Mayo Clin Proc; 2020 Sep; 95(9):1964-1977. PubMed ID: 32446635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment interventions to maintain abstinence from alcohol in primary care: systematic review and network meta-analysis.
    Cheng HY; McGuinness LA; Elbers RG; MacArthur GJ; Taylor A; McAleenan A; Dawson S; López-López JA; Higgins JPT; Cowlishaw S; Lingford-Hughes A; Hickman M; Kessler D
    BMJ; 2020 Nov; 371():m3934. PubMed ID: 33239318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
    Maisel NC; Blodgett JC; Wilbourne PL; Humphreys K; Finney JW
    Addiction; 2013 Feb; 108(2):275-93. PubMed ID: 23075288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repurposing drugs for treatment of alcohol use disorder.
    Aubin HJ
    Int Rev Neurobiol; 2024; 175():153-185. PubMed ID: 38555115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Medical management of alcohol use disorders].
    Paille F
    Rev Prat; 2019 Oct; 69(8):909-916. PubMed ID: 32237660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
    Bouza C; Angeles M; Muñoz A; Amate JM
    Addiction; 2004 Jul; 99(7):811-28. PubMed ID: 15200577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
    Klemperer EM; Hughes JR; Naud S
    Drug Alcohol Depend; 2018 Sep; 190():229-234. PubMed ID: 30059816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
    Tyson LD; Cheng A; Kelleher C; Strathie K; Lovendoski J; Habtemariam Z; Lewis H
    Eur J Gastroenterol Hepatol; 2022 May; 34(5):567-575. PubMed ID: 35421022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.
    Bahji A; Bach P; Danilewitz M; Crockford D; El-Guebaly N; Devoe DJ; Saitz R
    Addiction; 2022 Oct; 117(10):2591-2601. PubMed ID: 35194860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
    Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
    JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review.
    Rosenstand NJ; Nielsen AS; Skøt L; Anhøj S; Nielsen DG; Højlund M; Mellentin AI
    Curr Neuropharmacol; 2024; 22(6):1129-1143. PubMed ID: 36582063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
    Soyka M; Chick J
    Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid antagonists for alcohol dependence.
    Srisurapanont M; Jarusuraisin N
    Cochrane Database Syst Rev; 2002; (2):CD001867. PubMed ID: 12076425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
    Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
    Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis.
    Rose AK; Jones A
    Addiction; 2018 Aug; 113(8):1396-1406. PubMed ID: 29479827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid antagonists for alcohol dependence.
    Rösner S; Hackl-Herrwerth A; Leucht S; Vecchi S; Srisurapanont M; Soyka M
    Cochrane Database Syst Rev; 2010 Dec; (12):CD001867. PubMed ID: 21154349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
    Soyka M; Friede M; Schnitker J
    Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.